Status: Recruiting
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
The purpose of this study is to evaluate the safety and the immune response of personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax) in combination with durvalumab and tremelimumab following front-line treatment in patients with advanced stage BTC.
Participants needed: 25
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsUpdated: May 8, 2026Locations: 1
Eligibility criteria
Age ≥18 years [+12]
Participation in another clinical study with an investigational product during t... [+37]